1. Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
   Carlo Visco et al, 2020, Cancers CrossRef
2. Correlation Study of PD-L1, CD4, CD8, and PD-1 in Primary Diffuse Large B-cell Lymphoma of the Central Nervous System
   Bo Liu et al, 2022, Pathology - Research and Practice CrossRef
3. In silico and in vivo analysis of TIPE1 expression in diffuse large B cell lymphoma
   Pei Shen et al, 2022 CrossRef
4. Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
   Giovanni Manfredi Assanto et al, 2023, Front. Oncol. CrossRef
5. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring
   Daniela Drandi et al, 2023 CrossRef
6. Good clinical response following Ibrutinib treatment of a rare case of lymphoplasmacytic lymphoma secreting IgA kappa paraprotein: A case report
   Dragomira Nikolova et al, 2024, Oncol Lett CrossRef
7. Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients
   Ahmed Talaat Hanbal et al, 2024, J Egypt Natl Canc Inst CrossRef